• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

华氏巨球蛋白血症:一名老年男性的临床表现、诊断与管理

Waldenstrom Macroglobulinemia: Clinical Presentation, Diagnosis, and Management in an Elderly Male.

作者信息

Shahab Shahman, Semerdzhiev Dimitar I, Reeves James, Daniel Amy, Martin David E, Sukpraprut-Braaten Suporn

机构信息

Medicine, Arkansas College of Osteopathic Medicine, Fort Smith, USA.

Medicine, Unity Health, Searcy, USA.

出版信息

Cureus. 2023 Aug 25;15(8):e44127. doi: 10.7759/cureus.44127. eCollection 2023 Aug.

DOI:10.7759/cureus.44127
PMID:37750145
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10518236/
Abstract

Waldenstrom macroglobulinemia (WM) is a rare lymphoproliferative disease that can have an ambiguous clinical presentation. A key component of the pathophysiology of WM is bone marrow infiltration, which most commonly presents as anemia. Other symptoms of WM tend to be generalized and non-specific, which presents a diagnostic challenge. This was the case with our patient as well, when he presented to our outpatient clinic with non-specific symptoms. We present a 79-year-old male with longstanding pancytopenia, polyarthralgia, bilateral pedal edema, decreased appetite, and increased bleeding from wounds. The patient had a complete blood count (CBC) and complete metabolic panel (CMP) done, confirming present anemia, which prompted inpatient treatment and an oncology workup, confirming WM. The patient began a zanubrutinib monotherapy regimen, showing improvement in his pancytopenia, polyarthralgia, and overall symptoms.

摘要

华氏巨球蛋白血症(WM)是一种罕见的淋巴增殖性疾病,临床表现可能不明确。WM病理生理学的一个关键组成部分是骨髓浸润,最常见的表现为贫血。WM的其他症状往往较为普遍且不具特异性,这给诊断带来了挑战。我们的患者也是如此,他因非特异性症状前来我们的门诊就诊。我们报告一例79岁男性患者,有长期全血细胞减少、多关节痛、双侧足背水肿、食欲减退以及伤口出血增多的症状。患者进行了全血细胞计数(CBC)和全代谢组检查(CMP),证实存在贫血,这促使其接受住院治疗并进行肿瘤学检查,最终确诊为WM。患者开始使用泽布替尼单药治疗方案,其全血细胞减少、多关节痛及总体症状均有所改善。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/336c/10518236/e45d3e3ae249/cureus-0015-00000044127-i01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/336c/10518236/e45d3e3ae249/cureus-0015-00000044127-i01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/336c/10518236/e45d3e3ae249/cureus-0015-00000044127-i01.jpg

相似文献

1
Waldenstrom Macroglobulinemia: Clinical Presentation, Diagnosis, and Management in an Elderly Male.华氏巨球蛋白血症:一名老年男性的临床表现、诊断与管理
Cureus. 2023 Aug 25;15(8):e44127. doi: 10.7759/cureus.44127. eCollection 2023 Aug.
2
Simple headache revealed a rare lymphoma: Waldenstrom macroglobulinemia with unique markers: a case report and review of the literature.简单的头痛揭示了一种罕见的淋巴瘤:华氏巨球蛋白血症,具有独特的标志物:病例报告及文献复习。
J Egypt Natl Canc Inst. 2022 Mar 7;34(1):10. doi: 10.1186/s43046-022-00107-6.
3
Coming of Age for BTK Inhibitor Therapy: A Review of Zanubrutinib in Waldenström Macroglobulinemia.BTK 抑制剂治疗时代的到来:泽布替尼治疗华氏巨球蛋白血症的综述。
Cells. 2022 Oct 19;11(20):3287. doi: 10.3390/cells11203287.
4
Beyond monoclonal gammopathy of undetermined significance, clinical spectrum of immunoglobulin M gammopathy: a case series with focus on the diagnostic and management challenges.除意义未明的单克隆丙种球蛋白病外,免疫球蛋白M丙种球蛋白病的临床谱:以诊断和管理挑战为重点的病例系列
Int J Hematol Oncol. 2023 Feb 24;12(2):IJH44. doi: 10.2217/ijh-2022-0006. eCollection 2023 Jun.
5
Diagnostic framing of IgM monoclonal gammopathy: Focus on Waldenström macroglobulinemia.免疫球蛋白 M 单克隆丙种球蛋白血症的诊断框架:重点关注华氏巨球蛋白血症。
Hematol Oncol. 2019 Apr;37(2):117-128. doi: 10.1002/hon.2539. Epub 2018 Sep 7.
6
Zanubrutinib in Treating Waldenström Macroglobulinemia, the Last Shall Be the First.泽布替尼治疗华氏巨球蛋白血症,后来者居上。
Ther Clin Risk Manag. 2022 Jun 23;18:657-668. doi: 10.2147/TCRM.S338655. eCollection 2022.
7
Case report: A rare case of coexisting Waldenstrom Macroglobulinemia and B-cell acute lymphoblastic leukemia with KMT2D and MECOM mutations.病例报告:伴有 KMT2D 和 MECOM 突变的瓦尔登斯特伦巨球蛋白血症和 B 细胞急性淋巴细胞白血病共存的罕见病例。
Front Immunol. 2022 Oct 17;13:1001482. doi: 10.3389/fimmu.2022.1001482. eCollection 2022.
8
Bing-Neel Syndrome: An Initial Manifestation of Waldenstrom Macroglobulinemia.宾-尼尔综合征:华氏巨球蛋白血症的首发表现
Cureus. 2021 Nov 9;13(11):e19402. doi: 10.7759/cureus.19402. eCollection 2021 Nov.
9
Bruton tyrosine kinase inhibitors for Waldenström macroglobulinemia: A review.布鲁顿酪氨酸激酶抑制剂治疗华氏巨球蛋白血症:综述。
J Oncol Pharm Pract. 2021 Dec;27(8):1993-1999. doi: 10.1177/10781552211038309. Epub 2021 Sep 24.
10
Waldenstrom's Macroglobulinemia: A case report.华氏巨球蛋白血症:一例报告。
J Family Med Prim Care. 2020 Mar 26;9(3):1768-1771. doi: 10.4103/jfmpc.jfmpc_972_19. eCollection 2020 Mar.

本文引用的文献

1
Waldenström macroglobulinemia.华氏巨球蛋白血症。
Klin Onkol. 2021 Fall;34(6):428-433. doi: 10.48095/ccko2021428.
2
Waldenström Macroglobulinemia: Clinical Presentation, Diagnosis, and Management.华氏巨球蛋白血症:临床表现、诊断与治疗
J Adv Pract Oncol. 2020 May-Jun;11(4):381-389. doi: 10.6004/jadpro.2020.11.4.5. Epub 2020 May 1.
3
A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: the ASPEN study.一项随机 3 期临床试验,比较 zanubrutinib 与 ibrutinib 在有症状的华氏巨球蛋白血症中的疗效:ASPEN 研究。
Blood. 2020 Oct 29;136(18):2038-2050. doi: 10.1182/blood.2020006844.
4
Waldenstrom's Macroglobulinemia: An Update.华氏巨球蛋白血症:最新进展
Mediterr J Hematol Infect Dis. 2018 Jan 1;10(1):e2018004. doi: 10.4084/MJHID.2018.004. eCollection 2018.
5
Waldenström Macroglobulinemia: Review of Pathogenesis and Management.华氏巨球蛋白血症:发病机制与治疗综述
Clin Lymphoma Myeloma Leuk. 2017 May;17(5):252-262. doi: 10.1016/j.clml.2017.02.028. Epub 2017 Mar 7.
6
Competing risk survival analysis in patients with symptomatic Waldenström macroglobulinemia: the impact of disease unrelated mortality and of rituximab-based primary therapy.有症状的华氏巨球蛋白血症患者的竞争风险生存分析:疾病无关死亡率及基于利妥昔单抗的初始治疗的影响
Haematologica. 2015 Nov;100(11):e446-9. doi: 10.3324/haematol.2015.124149. Epub 2015 Aug 20.
7
Overall survival and competing risks of death in patients with Waldenström macroglobulinaemia: an analysis of the Surveillance, Epidemiology and End Results database.华氏巨球蛋白血症患者的总生存期和死亡的竞争风险:监测、流行病学和最终结果数据库分析
Br J Haematol. 2015 Apr;169(1):81-9. doi: 10.1111/bjh.13264. Epub 2014 Dec 18.
8
A new era for Waldenstrom macroglobulinemia: MYD88 L265P.华氏巨球蛋白血症的新纪元:MYD88 L265P。
Blood. 2013 May 30;121(22):4434-6. doi: 10.1182/blood-2013-04-494849.
9
Waldenström macroglobulinemia.华氏巨球蛋白血症
Blood. 2007 Jun 15;109(12):5096-103. doi: 10.1182/blood-2006-11-055012. Epub 2007 Feb 15.